West Paces Advisors’s West Pharmaceutical WST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.18K Buy
+20
New +$6.12K ﹤0.01% 417
2025
Q2
– Sell
-21
Closed -$4.7K – 568
2025
Q1
$4.7K Sell
21
-1
-5% -$276 ﹤0.01% 388
2024
Q4
$7.21K Hold
22
– – ﹤0.01% 368
2024
Q3
$6.6K Hold
22
– – ﹤0.01% 375
2024
Q2
$7.25K Hold
22
– – ﹤0.01% 372
2024
Q1
$8.71K Hold
22
– – ﹤0.01% 372
2023
Q4
$7.75K Hold
22
– – ﹤0.01% 382
2023
Q3
$8.26K Hold
22
– – ﹤0.01% 362
2023
Q2
$8.41K Hold
22
– – ﹤0.01% 383
2023
Q1
$7.62K Buy
22
+20
+1,000% +$5.84K ﹤0.01% 389
2022
Q4
$471 Buy
+2
New +$474 ﹤0.01% 511
2022
Q3
– Sell
-38
Closed -$11.5K – 586
2022
Q2
$11.5K Hold
38
– – ﹤0.01% 357
2022
Q1
$15.6K Hold
38
– – ﹤0.01% 336
2021
Q4
$17.8K Buy
38
+3
+9% +$1.29K 0.01% 324
2021
Q3
$14.9K Hold
35
– – 0.01% 322
2021
Q2
$12.6K Buy
+35
New +$11.6K ﹤0.01% 339

Other funds holding WST

West Paces Advisors's WST Position: Q2 2026 in Review

West Paces Advisors opened a new position in West Pharmaceutical (WST) in Q2 2026: 20 shares worth $7.18K. The stake represents ﹤0.01% of the portfolio and ranks #417 among its holdings. This is a return to the name: West Paces Advisors previously reported a position in WST as recently as Q1 2025.

West Paces Advisors first reported a position in WST in Q2 2021 and has held it in 16 quarters since. The position peaked at $17.8K in Q4 2021. 834 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • West Paces Advisors held 20 shares of West Pharmaceutical worth $7.18K as of Q2 2026.
  • West Pharmaceutical was a new West Paces Advisors position in Q2 2026.
  • West Pharmaceutical made up ﹤0.01% of West Paces Advisors's portfolio in Q2 2026, its #417 holding.
  • West Paces Advisors first reported a position in West Pharmaceutical in Q2 2021 and has held it in 16 quarters since.
  • West Paces Advisors's West Pharmaceutical position peaked at $17.8K in Q4 2021.
  • 834 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on West Paces Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.